Diametric Capital, LP Akebia Therapeutics, Inc. Call Options Transaction History
Diametric Capital, LP
- $118 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AKBA
# of Institutions
128Shares Held
63.3MCall Options Held
50.6KPut Options Held
203K-
Black Rock Inc. New York, NY11.6MShares$24.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$22.9 Million0.0% of portfolio
-
State Street Corp Boston, MA6.3MShares$13.2 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$12.1 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA4.8MShares$10.1 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $386M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...